Global Oncology Academy

Contrasting TROP2-Targeted ADCs in Breast Cancer Therapy
Contrasting TROP2-Targeted ADCs in Breast Cancer Therapy
CME/CE
Contrasting TROP2-Targeted ADCs in Breast Cancer Therapy
0.50 credits
- Kevin Kalinsky MD, MS
- Komal Jhaveri, MD, FACP
0.50 credits
Assessing Efficacy and Cost of Blood-Based Tests for Colorectal Cancer
Assessing Efficacy and Cost of Blood-Based Tests for Colorectal Cancer
Clinician's Roundtable
Assessing Efficacy and Cost of Blood-Based Tests for Colorectal Cancer
- Charles Turck, PharmD, BCPS, BCCCP
- Samuel Muench, MD
Biomarker Breakthroughs: A Look at What’s Next for Kidney Cancer Care
Biomarker Breakthroughs: A Look at What’s Next for Kidney Cancer Care
Project Oncology®
Biomarker Breakthroughs: A Look at What’s Next for Kidney Cancer Care
- Ryan Quigley
- David F. McDermott, MD
Uncovering Unmet Needs in Squamous Cell Carcinoma of the Anal Canal Care
Uncovering Unmet Needs in Squamous Cell Carcinoma of the Anal Canal Care
Project Oncology®
Uncovering Unmet Needs in Squamous Cell Carcinoma of the Anal Canal Care
- Richard Kim, MD
Subcutaneous Cancer Immunotherapy at Home: Transforming Trials and Patient Care
Subcutaneous Cancer Immunotherapy at Home: Transforming Trials and Patient Care
Project Oncology®
Subcutaneous Cancer Immunotherapy at Home: Transforming Trials and Patient Care
- Jorge Nieva, MD
New Frontiers in the Imaging and Treatment of Advanced Prostate Cancer
New Frontiers in the Imaging and Treatment of Advanced Prostate Cancer
Global Oncology Academy
New Frontiers in the Imaging and Treatment of Advanced Prostate Cancer
- Wayne Kuang, MD
- William Oh, MD
Bringing Cancer Care Home: How Subcutaneous Immunotherapy Can Help Ease the Burden
Bringing Cancer Care Home: How Subcutaneous Immunotherapy Can Help Ease the Burden
Project Oncology®
Bringing Cancer Care Home: How Subcutaneous Immunotherapy Can Help Ease the Burden
- Jorge Nieva, MD
Why Words Matter: Rethinking Terminology in Advanced Prostate Cancer
Why Words Matter: Rethinking Terminology in Advanced Prostate Cancer
Global Oncology Academy
Why Words Matter: Rethinking Terminology in Advanced Prostate Cancer
- William Oh, MD

Medical News

Medical News
Prognostic Impact of Para-Aortic Lymph Node Metastasis in Endometrial Cancer
07/18/2025
Read more
Medical News
Overcoming Chemotherapy Resistance in Bladder Cancer: The Role of Inflammatory Pathways and TRIM Proteins
07/18/2025
Read more
Medical News
Revolutionizing Prostate Cancer Care with PSMA PET/CT and AI-Driven Innovations
07/18/2025
Read more
Medical News
Transformative Molecular and Immune Strategies in Pancreatic Ductal Adenocarcinoma (PDAC)
07/17/2025
Read more

See more news

CME/CE

First-line Chemotherapy Options in Metastatic PDAC
First-line Chemotherapy Options in Metastatic PDAC
MinuteCE®
First-line Chemotherapy Options in Metastatic PDAC
0.25 program credits
- Eileen O’Reilly, MD
0.25 program credits
MinuteCE®
Chemotherapy Strategies in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
0.25 credits 2 episodes
- Eileen O’Reilly, MD
- Efrat Dotan, MD
0.25 credits 2 episodes
MinuteCE®
Mastering Mutation-Driven mCRC: From Testing to Targeted Therapy
1.00 credit 5 episodes
- Jenny Seligmann, MBChB, PhD
- Fortunato Ciardiello, MD, PhD
- Scott Kopetz, MD, PhD
- Cathy Eng, MD, FACP
1.00 credit 5 episodes
Mutational Testing in mCRC: Methods and Data Driving Treatment Selection
Mutational Testing in mCRC: Methods and Data Driving Treatment Selection
MinuteCE®
Mutational Testing in mCRC: Methods and Data Driving Treatment Selection
1.00 program credit
- Fortunato Ciardiello, MD, PhD
- Jenny Seligmann, MBChB, PhD
1.00 program credit

Clinical Practice

DLL3 Expression in GEP-NECs: A Marker of Poor Differentiation and Emerging Therapeutic Target
DLL3 Expression in GEP-NECs: A Marker of Poor Differentiation and Emerging Therapeutic Target
Project Oncology®
DLL3 Expression in GEP-NECs: A Marker of Poor Differentiation and Emerging Therapeutic Target
Liquid Biopsy for Colorectal Cancer Screening: Benefits and Barriers
Liquid Biopsy for Colorectal Cancer Screening: Benefits and Barriers
Clinician's Roundtable
Liquid Biopsy for Colorectal Cancer Screening: Benefits and Barriers
- Charles Turck, PharmD, BCPS, BCCCP
- Brennan Spiegel, MD, MSHS
Studying Carboplatin-Paclitaxel + Retifanlimab for Squamous Cell Carcinoma of the Anal Canal
Studying Carboplatin-Paclitaxel + Retifanlimab for Squamous Cell Carcinoma of the Anal Canal
Project Oncology®
Studying Carboplatin-Paclitaxel + Retifanlimab for Squamous Cell Carcinoma of the Anal Canal
- Charles Turck, PharmD, BCPS, BCCCP
- Richard Kim, MD
Early-Onset Endometrial Cancer: Bridging the Gap Between Age and Outcome
Early-Onset Endometrial Cancer: Bridging the Gap Between Age and Outcome
Project Oncology®
Early-Onset Endometrial Cancer: Bridging the Gap Between Age and Outcome

Programs

Optimizing Nivolumab in NSCLC: Implications for Cost, Access, and Outcomes
Optimizing Nivolumab in NSCLC: Implications for Cost, Access, and Outcomes
Project Oncology®
Optimizing Nivolumab in NSCLC: Implications for Cost, Access, and Outcomes
- Aline Fares, MD
One Year or Two? DANTE Trial Explores Immunotherapy Duration in Metastatic Melanoma
One Year or Two? DANTE Trial Explores Immunotherapy Duration in Metastatic Melanoma
Project Oncology®
One Year or Two? DANTE Trial Explores Immunotherapy Duration in Metastatic Melanoma
Unpacking the Logistics of At-Home Subcutaneous Cancer Immunotherapy Delivery
Unpacking the Logistics of At-Home Subcutaneous Cancer Immunotherapy Delivery
Project Oncology®
Unpacking the Logistics of At-Home Subcutaneous Cancer Immunotherapy Delivery
- Jorge Nieva, MD
Investigating At-Home Subcutaneous Atezolizumab for NSCLC: An Ongoing Study
Investigating At-Home Subcutaneous Atezolizumab for NSCLC: An Ongoing Study
Project Oncology®
Investigating At-Home Subcutaneous Atezolizumab for NSCLC: An Ongoing Study
- Jorge Nieva, MD